Michael Gelband ExodusPoint Capital Management
Michael Gelband is a co-founder of ExodusPoint Capital Management, a multi-strategy hedge fund launched by veterans of larger alternative platforms. The firm pursues diversified strategies across asset classes with a focus on risk-managed absolute returns. Gelband’s firm is followed as part of the newer generation of multi-strategy complexes.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$689M |
| 2 |
Broadcom
AVGO
|
+$153M |
| 3 |
Walmart Inc
WMT
|
+$136M |
| 4 |
Amazon
AMZN
|
+$104M |
| 5 |
iShares Core S&P 500 ETF
IVV
|
+$102M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$71.5M |
| 2 |
Pinnacle West Capital
PNW
|
+$49.1M |
| 3 |
Procter & Gamble
PG
|
+$43.7M |
| 4 |
Chevron
CVX
|
+$43.1M |
| 5 |
Hershey
HSY
|
+$43M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.62% |
| 2 | Healthcare | 9.42% |
| 3 | Industrials | 7.55% |
| 4 | Financials | 6.82% |
| 5 | Consumer Discretionary | 6.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
DHC
1276
Diversified Healthcare Trust
DHC
$1.94B
| $337K | ﹤0.01% |
+69,400
| New | +$315K |
|
1277
Plug Power
PLUG
$3.06B
| $336K | ﹤0.01% |
170,364
-864,600
| -84% | -$2.26M |
|
1278
Alto Neuroscience
ANRO
$1.44B
| $334K | ﹤0.01% |
+18,786
| New | +$237K |
|
|
NMAX
1279
Newsmax Inc
NMAX
$1.38B
| $334K | ﹤0.01% |
+43,242
| New | +$415K |
|
1280
Bioventus
BVS
$954M
| $334K | ﹤0.01% |
+44,907
| New | +$323K |
|
1281
Relmada Therapeutics
RLMD
$491M
| $333K | ﹤0.01% |
+68,883
| New | +$231K |
|
1282
Southern Missouri Bancorp
SMBC
$820M
| $330K | ﹤0.01% |
+5,583
| New | +$309K |
|
1283
SIGA Technologies
SIGA
$214M
| $330K | ﹤0.01% |
54,014
+21,110
| +64% | +$150K |
|
|
TDAY
1284
USA Today Co
TDAY
$941M
| $330K | ﹤0.01% |
+64,059
| New | +$301K |
|
1285
Kiniksa Pharmaceuticals
KNSA
$6.16B
| $328K | ﹤0.01% |
7,958
-51,918
| -87% | -$2.08M |
|
|
SLDE
1286
Slide Insurance Holdings
SLDE
$2.75B
| $328K | ﹤0.01% |
+16,840
| New | +$281K |
|
1287
REX American Resources
REX
$1.4B
| $328K | ﹤0.01% |
10,141
-24,430
| -71% | -$796K |
|
1288
Kelly Services Class A
KELYA
$587M
| $325K | ﹤0.01% |
+36,986
| New | +$376K |
|
1289
Ardelyx
ARDX
$968M
| $325K | ﹤0.01% |
55,731
-79,125
| -59% | -$441K |
|
1290
NWPX Infrastructure Inc
NWPX
$1.07B
| $325K | ﹤0.01% |
+5,196
| New | +$300K |
|
|
KALV
1291
DELISTED
KalVista Pharmaceuticals
KALV
| $324K | ﹤0.01% |
+20,061
| New | +$266K |
|
1292
Neumora Therapeutics
NMRA
$299M
| $324K | ﹤0.01% |
+180,856
| New | +$396K |
|
1293
SAB Biotherapeutics
SABS
$337M
| $322K | ﹤0.01% |
+86,113
| New | +$283K |
|
|
MITT
1294
TPG Mortgage Investment Trust
MITT
$213M
| $322K | ﹤0.01% |
+37,790
| New | +$296K |
|
1295
Custom Truck One Source
CTOS
$2.21B
| $320K | ﹤0.01% |
+55,498
| New | +$339K |
|
1296
Scansource
SCSC
$1.09B
| $320K | ﹤0.01% |
8,184
-30,778
| -79% | -$1.27M |
|
1297
Li Auto
LI
$12.2B
| $319K | ﹤0.01% |
+18,859
| New | +$374K |
|
1298
Highwoods Properties
HIW
$3.5B
| $318K | ﹤0.01% |
+12,303
| New | +$347K |
|
1299
X4 Pharmaceuticals
XFOR
$404M
| $316K | ﹤0.01% |
+79,072
| New | +$287K |
|
1300
Matrix Service
MTRX
$301M
| $316K | ﹤0.01% |
27,011
-17,039
| -39% | -$214K |
|
Similar funds
Michael Gelband's Q4 2025 Portfolio in Review
As of Q4 2025, Michael Gelband held 2,189 positions worth $12.7B, up 30% from $9.79B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Michael Gelband deployed $2.85B of net new capital in Q4 2025, opening 723 new positions and adding to 409 existing holdings. Its largest new stake was iShares Core S&P 500 ETF: 150,000 shares worth $103M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 15% a quarter earlier, followed by Healthcare and Industrials.
On the sell side, the largest reduction was Procter & Gamble, an estimated $43.7M trimmed.
- Michael Gelband's largest Q4 2025 buy was iShares Core S&P 500 ETF: 150,000 shares worth $103M.
- Michael Gelband added most to NVIDIA in Q4 2025, an estimated $689M increase.
- Michael Gelband's biggest Q4 2025 reduction was Procter & Gamble, cutting an estimated $43.7M.
- Michael Gelband fully exited Meta Platforms (Facebook) in Q4 2025, selling an estimated $71.5M.
- Michael Gelband's ten largest holdings make up 30% of its $12.7B portfolio in Q4 2025.
- Michael Gelband opened 723 new positions and closed 716 in Q4 2025.
- Michael Gelband's portfolio value rose 30% quarter-over-quarter to $12.7B.
Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.